Novocure Announces First Analysis of Full 700 Patient Dataset from Successful Newly Diagnosed GBM Phase III Trial

Full dataset analysis confirms study met its endpoints, extending both progression-free and overall survival of newly diagnosed GBM patients ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that the first analysis of all 700 newly diagnosed glioblastoma (GBM) patients enrolled in its EF-14 Phase III trial confirms that Tumor Treating Fields (TTFields) …

Novocure Hosts First Glioblastoma-focused Hackathon to Develop New Support Tools for the GBM Brain Cancer Community

Technology experts and cancer patient advocates will #HackGBM in Chicago this week NEW YORK–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, today kicks off Hack GBM: Finding Support Solutions for Glioblastoma Community Challenges, the first-ever hackathon to specifically address the needs of the glioblastoma (GBM) community. The hackathon will unite advocates and tech experts to develop …

Novocure Announces Commercial Launch of Optune (the NovoTTF-100A System) in Japan

Optune, a Tumor Treating Fields delivery system, provides a novel, non-invasive treatment for recurrent glioblastoma, the most common malignant primary brain cancer ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that 31 neurosurgeons at medical centers across Japan are trained and certified to prescribe Optune. These physicians are now able to treat …

Novocure to Present New Clinical and Preclinical Data on Tumor Treating Fields at the American Society of Clinical Oncology Annual Meeting 2015

Presentation by Roger Stupp, MD will be the first report on the full 700 patient population that enrolled to the EF-14 trial in newly diagnosed glioblastoma ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that data from pre-clinical and clinical studies demonstrating the latest understanding of Tumor Treating Fields (TTFields) will be …

FDA Grants Priority Review Status for Novocure’s PMA Supplement Application of Optune in Newly Diagnosed Glioblastoma

PMA Supplement application for Tumor Treating Fields in combination with temozolomide chemotherapy for newly diagnosed glioblastoma accepted for filing and review ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that its Premarket Approval (PMA) application for Optune has been accepted for filing and review and granted priority review status by the United …

NCCN Guidelines Recommend Tumor Treating Fields as a Standard Treatment Option for Recurrent Glioblastoma

Optune, a Tumor Treating Fields delivery system, provides a non-invasive, low-toxicity, home-use treatment for recurrent glioblastoma, the most common malignant primary brain cancer ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that Optune has been added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central …

Novocure Kicks Off Brain Tumor Awareness Month with New Activities to Address Challenges in the Glioblastoma Community

Tune-In to GBM initiative will culminate in first GBM Hackathon event to find innovative solutions for patients and caregivers NEW YORK–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that it is sponsoring its Tune-In to GBM campaign during Brain Tumor Awareness Month for the third consecutive year. Novocure is launching a series of activities …